证券代码：002294 证券简称：信立泰 编号：2023-022 深圳信立泰药业股份有限公司 本次网上业绩说明会将采用网络文字互动的方式举行，投资者可于 2023 年 4 月 14 日（星期五）15:00-17:00 通过网址 https://eseb.cn/13HOQ5zw0qA 或使用 微信扫描下方小程序码即可进入参与互动交流。 为广泛听取投资者的意见和建议，公司提前向投资者征集问题，投资者可于 2023 年 4 月 14 日前进行会前提问，公司将通过本次业绩说明会，在信息披露允 许范围内就投资者普遍关注的问题进行回答。 出席本次说明会的人员有：董事、总经理颜杰先生，独立董事王学恭先生， 财务负责人孔芸女士，董事、董事会秘书杨健锋先生。 欢迎广大投资者积极参与！ 关于举行 2022 年年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳信立泰药业股份有限公司（下称"公司"）《2022 年年度报告》、《2022 年年度报告摘要》已于 2023 年 3 月 29 日披露。 为便于广大投资者进一步了解公司 2022 年度经营情况等，公司将于 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB in 2022, representing a growth of 20% compared to the previous year[10]. - The company's operating revenue for 2022 was ¥3,482,011,378.10, representing a 13.85% increase from ¥3,058,392,041.37 in 2021[16]. - Net profit attributable to shareholders for 2022 was ¥636,943,594.06, a 19.34% increase from ¥533,726,576.95 in 2021[16]. - The net profit after deducting non-recurring gains and losses for 2022 was ¥551,815,169.06, showing a significant increase of 94.77% compared to ¥283,309,767.44 in 2021[16]. - The company achieved a revenue of 3.482 billion yuan in 2022, representing a year-on-year growth of 13.85%[25]. - The company reported a total of ¥85,128,425.00 in non-recurring gains for 2022, down from ¥250,416,809.51 in 2021[21]. - The company’s cash flow from operating activities for 2022 was ¥970,804,863.11, a decrease of 18.07% from ¥1,184,978,525.65 in 2021[16]. - The company’s total sales expenses increased by 5.65% to ¥1,094,427,270.13 compared to the previous year[48]. - The company’s total profit available for distribution to investors in 2022 was CNY 5,002,893,148.11, with a cash dividend distribution of CNY 545,679,506.00, representing 128.73% of the net profit attributable to ordinary shareholders[170]. Research and Development - The company has approximately 60 innovative products in the research and development pipeline, with some at a globally leading level[7]. - Research and development investments increased by 30% in 2022, focusing on innovative drug formulations and advanced technologies[10]. - The company is focusing on innovative drug development, particularly in the fields of cardiovascular and chronic disease management, aligning with national health strategies[23]. - The company has submitted 6 new drug IND applications and 2 new product registration applications during the reporting period[28]. - The company achieved a total R&D investment of approximately ¥917.50 million in 2022, representing a year-on-year increase of 32.69% from ¥691.48 million in 2021[59]. - The number of R&D personnel increased by 18.15% to 755 in 2022, compared to 639 in 2021, with the proportion of R&D staff rising from 19.75% to 21.86%[58]. - The company has received 28 new patent authorizations in 2022, including 22 invention patents and 6 utility model patents, enhancing its intellectual property portfolio[57]. - The company is advancing multiple research and development projects across various stages, including 14 chemical drug projects and 6 biological drug projects[51]. Market Expansion and Product Development - The company plans to launch around two innovative products each year, including recent products with significant efficacy and safety advantages[7]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[10]. - The company aims to enhance its market position by expanding its product offerings in cardiovascular and orthopedic treatments, leveraging its research capabilities[24]. - The company is focusing on expanding its product lines in cardiovascular, diabetes, orthopedics, oncology, and anti-infection areas[89]. - The company is pursuing an IPO for its medical device segment and plans to seek overseas financing for global product development[91]. - The company plans to achieve 2 NDA submissions and 3 IND applications for innovative products in 2023, enhancing its product pipeline[91]. - The company is actively participating in national drug procurement, which has provided stable cash flow and operational improvements[30]. Strategic Initiatives and Acquisitions - A strategic acquisition of a biotech firm was completed, enhancing the company's capabilities in drug development and increasing its product pipeline[10]. - The company is considering strategic acquisitions to enhance its product portfolio, with a target of identifying at least two potential acquisition candidates by mid-2023[143]. - The company has established partnerships with three major hospitals to facilitate clinical trials for new drugs, aiming to expedite the approval process[10]. Risk Management and Challenges - The company acknowledges potential risks such as R&D failures and policy changes that could impact pricing and costs[3]. - The company is facing risks related to R&D failures, policy changes affecting drug pricing, and rising costs of raw materials and labor[93][94]. - The company has established comprehensive internal control and risk management systems to mitigate market, liquidity, credit, operational, and legal risks associated with derivative investments[74]. Corporate Governance and Shareholder Engagement - The company has continuously improved its corporate governance structure and internal control systems[97]. - The company held two shareholder meetings during the reporting period, ensuring equal rights for all shareholders, especially minority shareholders[102]. - The company has established a transparent decision-making process for profit distribution, ensuring that minority shareholders have the opportunity to express their opinions[168]. - The company has a well-structured board with independent directors fulfilling their supervisory roles[104]. - The company has implemented various management systems to ensure compliance and transparency in operations[98]. Sustainability and Environmental Compliance - The company emphasizes sustainable development and aims to maximize shareholder and company interests[97]. - The company has been recognized as a key pollutant discharge unit by local environmental protection authorities, with its manufacturing plants adhering to strict environmental standards[195]. - The company has implemented various environmental protection measures, including the establishment of a "Safety Production Committee" and dedicated HSE management teams across its subsidiaries[195]. - The company complies with multiple environmental laws and standards, ensuring stable operation of its waste treatment facilities[196]. Employee Management and Development - The company has implemented a training program that includes various levels of training for employees, enhancing management capabilities and professional skills[162]. - The company emphasizes the importance of talent development, providing resources and platforms for employee growth and supporting the establishment of a talent reserve[162]. - The company has implemented a second employee stock ownership plan, significantly enhancing the motivation and retention of key employees[160]. - The total number of employees at the end of the reporting period was 3,454, with 2,344 in the parent company and 1,110 in major subsidiaries[158].

Group 1: Product Performance - Clopidogrel is primarily used in PCI procedures, with significant applications in therapeutic prevention and neurology [1] - The product "Taijia" has maintained stable growth this year, although the growth rate has slightly slowed due to a high base [2] - The sales of "Xinglitai" are currently focused on bidding and academic promotion, with lower sales expected this year due to its recent launch [2] Group 2: Market and Regulatory Environment - The national bidding situation emphasizes quality and follows government guidelines, encouraging domestic manufacturers to reach international standards [2] - The company’s overall bidding success remains good, with specific details available on the drug bidding website [2] Group 3: Research and Development - The patent for "Xinglitai" protects both the compound and the synthesis method, expiring in 2026 [3] - The company is exploring opportunities in the medical services sector, supported by government policies, but emphasizes the need for detailed feasibility studies before proceeding [3] - The stent project has completed multi-center randomized controlled clinical trials, with production application expected after the clinical report is finalized by the end of this year [3] Group 4: Future Product Pipeline - The company has multiple products in development, focusing on high-end prescription drugs and biomedicine, although it is difficult to identify which will be blockbuster products [4]

Group 1: Financial Insights - PCI surgery costs generally exceed tens of thousands of yuan, while the annual cost of using Taijia is no more than 4,000 yuan, representing a low proportion of overall expenses [2] - The domestic market for PCI surgeries is expected to continue growing in the next few years, as the current volume is far from saturation compared to developed countries [3] - The company anticipates gradual sales growth for Xintan as bidding processes progress, despite initial low sales due to its recent market entry [3] Group 2: Market Dynamics - Clopidogrel is primarily used in secondary and tertiary hospitals, with its growth driven by these institutions, although there may be some uplift in grassroots markets [2] - The domestic population suffering from hypertension has reached 200 million, indicating a significant market expansion potential due to aging demographics [4] - The company’s sales team consists of approximately 1,000 personnel, indicating a robust structure for market penetration [4] Group 3: Product Development and Strategy - Xintan is classified as a Class 1 new drug with over ten years of patent protection, which is a key factor for the company's confidence in its market prospects [3] - The company is focusing on academic promotion and bidding participation for Xintan, with expectations of increased sales as these efforts mature [3] - The company is exploring potential acquisitions in the medical services sector, driven by favorable government policies, although thorough feasibility studies are required before proceeding [5]